Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab with sequential versus concurrent oral vinorelbine plus capecitabine in locally advanced or recurrent breast cancer with chest wall lymphangitic spread
2006-002152-16Phase 2Completed
- Sponsor
- European Institute of Oncology
- Start
- Jul 2007
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab, vinorelbine and capecitabine in breast cancer (2 arms), sponsored by European Institute of Oncology. Started Jul 2007; status: completed.
02
Drugs
bevacizumabvinorelbinecapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2006-002152-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002152-16.